Antibody Drug Conjugates in Lung Cancer: State of the Current Therapeutic Landscape and Future Developments

Joshua E. Reuss, Laura Gosa, Stephen V. Liu

Research output: Contribution to journalReview articlepeer-review


While both targeted therapy and immunotherapy-based strategies have emerged as frontline standard-of-care for patients with advanced lung cancer, acquired resistance and disease progression remain inevitable in most cases. Chemotherapy is a common salvage option in this scenario, but is limited by a relatively narrow therapeutic index. The emergence of antibody-drug conjugates (ADCs) offer an appealing alternative. ADCs couple the specificity of a monoclonal antibody with the cytotoxic effects of chemotherapy to facilitate the targeted delivery of cytotoxic payloads directly to cancer cells. Here, we review the general structure and function of ADCs, followed by a discussion of emerging ADCs in lung cancer and the future applications of this increasingly relevant class of novel agents.

Original languageEnglish (US)
Pages (from-to)483-499
Number of pages17
JournalClinical lung cancer
Issue number6
StatePublished - Nov 2021


  • ADC
  • Review
  • SCLC
  • Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this